TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: To explore whether miR-155 can make CD34+ chronic myeloid leukemia (CML) cells eliminate the growth inhibition of TGF-β1 and signal transduction of bone morphogenetic protein (BMP), miR-155 was overexpressed, which significantly promoted the proliferation rate of CD34+ CML cells [17].